Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19397285 | 0.77 | NOTUM (0.47) | NOTUMALDH1A1MAPTLMNAHTT | |
| SCHEMBL19381177 | 0.75 | NOTUM (0.45) | NOTUMALDH1A1MAPTLMNAHTT | |
| SCHEMBL917714 | 0.74 | NOTUM (0.67) | NOTUMALDH1A1MAPTLMNAHTT | |
| SCHEMBL20153305 | 0.74 | NOTUM (0.56) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL14919351 | 0.74 | SMN1; SMN2 (0.48) | NOTUMALDH1A1MAPTLMNAKCNJ1 | |
| SCHEMBL20342425 | 0.74 | NOTUM (0.44) | NOTUMALDH1A1MAPTLMNAHTT | |
| SCHEMBL14919327 | 0.73 | TP53 (0.66) | NOTUMALDH1A1MAPTKCNJ1KMT2A | |
| SCHEMBL82595 | 0.72 | MAPT (0.69) | NOTUMALDH1A1MAPTLMNAHTT | |
| SCHEMBL21863404 | 0.72 | CHRNB2 (0.40) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL15018386 | 0.72 | KCNJ1 (0.51) | ALDH1A1MAPTKCNJ1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| WO-2016100347-A2 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | NOTUM 2800/4885ALDH1A1 4653/4885MAPT 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.